Fed. Circ. Affirms Invalidity Of J&J Stent Patents

Law360, New York (June 7, 2011, 3:51 PM EDT) -- The Federal Circuit on Tuesday upheld a determination that four Johnson & Johnson patents for drug-eluting stents were invalid for lack of adequate written description, handing a victory to Boston Scientific Corp.

The appeals court rejected J&J's contention that a Delaware federal court had improperly granted summary judgment to BSC, finding that the lower court had correctly ruled that the four patents did not contain proper written descriptions and were therefore invalid.

The companies have been embroiled in patent infringement litigation over various stents for more...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.